Replimune Group (NASDAQ:REPL) Trading Up 3.7%

Shares of Replimune Group, Inc. (NASDAQ:REPL) shot up 3.7% during mid-day trading on Friday . The stock traded as high as $8.25 and last traded at $8.16. 163,231 shares traded hands during trading, a decline of 87% from the average session volume of 1,276,234 shares. The stock had previously closed at $7.87.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on REPL. Wedbush reaffirmed an “outperform” rating and set a $16.00 price target on shares of Replimune Group in a research note on Thursday, June 6th. HC Wainwright lifted their price objective on Replimune Group from $12.00 to $17.00 and gave the stock a “buy” rating in a report on Friday, June 7th. Finally, Barclays lifted their price objective on Replimune Group from $13.00 to $17.00 and gave the stock an “overweight” rating in a report on Friday, June 7th.

Replimune Group Stock Performance

The company has a market cap of $522.03 million, a PE ratio of -2.62 and a beta of 1.15. The company has a current ratio of 10.72, a quick ratio of 10.72 and a debt-to-equity ratio of 0.18. The business has a fifty day moving average of $6.72 and a 200-day moving average of $7.56.

Replimune Group (NASDAQ:REPL) last announced its quarterly earnings results on Thursday, May 16th. The company reported ($0.82) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.86) by $0.04. Equities research analysts anticipate that Replimune Group, Inc. will post -3.31 earnings per share for the current fiscal year.

Insider Activity at Replimune Group

In other Replimune Group news, Chairman Philip Astley-Sparke sold 37,928 shares of Replimune Group stock in a transaction that occurred on Thursday, May 16th. The stock was sold at an average price of $6.47, for a total transaction of $245,394.16. Following the sale, the chairman now directly owns 1,487,350 shares of the company’s stock, valued at approximately $9,623,154.50. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other Replimune Group news, insider Konstantinos Xynos sold 15,881 shares of Replimune Group stock in a transaction that occurred on Friday, June 7th. The stock was sold at an average price of $7.50, for a total transaction of $119,107.50. Following the sale, the insider now directly owns 117,131 shares of the company’s stock, valued at approximately $878,482.50. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Chairman Philip Astley-Sparke sold 37,928 shares of the business’s stock in a transaction that occurred on Thursday, May 16th. The stock was sold at an average price of $6.47, for a total value of $245,394.16. Following the completion of the sale, the chairman now directly owns 1,487,350 shares in the company, valued at $9,623,154.50. The disclosure for this sale can be found here. Insiders have sold a total of 107,598 shares of company stock worth $712,516 in the last 90 days. Company insiders own 20.60% of the company’s stock.

Institutional Trading of Replimune Group

A number of hedge funds have recently made changes to their positions in the stock. Price T Rowe Associates Inc. MD boosted its position in shares of Replimune Group by 12.0% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 6,548,930 shares of the company’s stock worth $53,505,000 after purchasing an additional 699,679 shares in the last quarter. Fcpm Iii Services B.V. bought a new stake in shares of Replimune Group in the 4th quarter worth approximately $41,024,000. Vanguard Group Inc. lifted its position in Replimune Group by 1.2% in the 1st quarter. Vanguard Group Inc. now owns 2,770,328 shares of the company’s stock valued at $22,634,000 after acquiring an additional 32,555 shares in the last quarter. Goldman Sachs Group Inc. boosted its stake in Replimune Group by 300.3% during the 4th quarter. Goldman Sachs Group Inc. now owns 2,238,883 shares of the company’s stock valued at $18,874,000 after purchasing an additional 1,679,553 shares during the last quarter. Finally, Rafferty Asset Management LLC boosted its stake in Replimune Group by 148.1% during the 4th quarter. Rafferty Asset Management LLC now owns 463,397 shares of the company’s stock valued at $3,906,000 after purchasing an additional 276,596 shares during the last quarter. 92.53% of the stock is owned by institutional investors.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.